Oparta (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Oparta is a combination inhaled therapy that targets airway inflammation and bronchoconstriction in chronic respiratory disease.

• Asthma: improves lung function and reduces the frequency of exacerbations.
• Chronic obstructive pulmonary disease (COPD): helps maintain airflow and decreases symptom variability.
• Exercise‑induced bronchoconstriction: provides pre‑exercise bronchodilation and inflammation control.

• Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, reducing the transcription of inflammatory cytokines and decreasing airway edema. Formoterol fumarate dihydrate activates β2‑adrenergic receptors, leading to increased cyclic AMP and smooth‑muscle relaxation, which together widen the airways and improve airflow.

Adverse reactions may occur with inhaled corticosteroid/long‑acting β2‑agonist combinations and should be monitored.

Common Side Effects

• Oral thrush (candidiasis): fungal growth in the mouth.
• Hoarseness: voice changes after inhalation.
• Cough: irritation of the throat.
• Headache: mild to moderate intensity.
• Nasal congestion: blockage of nasal passages.
• Upper respiratory tract infection: mild viral symptoms.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Pneumonia: lung infection, especially in COPD patients.
• Adrenal suppression: reduced cortisol production with prolonged high‑dose use.
• Glaucoma or cataracts: increased intra‑ocular pressure or lens opacity.
• Severe allergic reaction: hives, swelling, or anaphylaxis.
• Osteoporosis: decreased bone mineral density with long‑term use.

When prescribing Oparta, clinicians should consider several safety aspects.

• Assess asthma or COPD control: ensure the patient remains stable on current therapy.
• Monitor for oral candidiasis: advise rinsing mouth after each inhalation.
• Evaluate cardiovascular risk: beta‑agonists can affect heart rate and blood pressure.
• Review concomitant medications: avoid excessive systemic corticosteroid exposure.
• Use the lowest effective dose: limit exposure to inhaled steroids.
• Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Oparta may interact with other medicines that influence the cardiovascular or immune systems.

Major Interactions (Avoid)

• Beta‑blockers: may diminish bronchodilator response and provoke bronchospasm.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase systemic exposure to beclometasone.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypokalemia risk when combined with long‑acting β2‑agonists.\n- Theophylline: may increase the risk of tachycardia and tremor.
• Non‑selective NSAIDs: can exacerbate asthma symptoms in sensitive individuals.
• Anticholinergic bronchodilators: additive bronchodilation may require dose adjustment.